Meconium and Umbilical Cord Cannabis Results Can Disagree Without Identifying Harm

Paired meconium and umbilical-cord specimens did not identify exactly the same cannabinoid exposures in a laboratory study. A negative cord result therefore did not reliably exclude a positive meconium result, and neither result independently established injury to the child.

Two matrices from the same birth

Researchers developed separate LC–MS/MS methods and examined 46 paired clinical specimens. The meconium panel included THC, a carboxy metabolite, 11-hydroxy-THC, cannabinol and CBD. CBD was excluded from the validated cord panel because recovery was inadequate.

The paper abbreviates 11-nor-9-carboxy-THC as “THCA.” In this context that abbreviation refers to the carboxy metabolite, not the similarly abbreviated acidic precursor in cannabis plants. Identifying the full compound name prevents a substantial interpretive error.

Agreement depended on positive versus negative results

The authors reported 100% negative agreement but only 59% positive agreement between matrices. Thirteen meconium-positive pairs had negative cord results. The analytical ranges and analyte profiles differed between the methods, so numerical concentrations were not interchangeable.

The paper contains inconsistent false-positive/false-negative wording when discussing the discrepant pairs. The concrete observation is clearer: some exposures detected in meconium were not detected in the paired cord specimen. Without an independent perfect reference, that should not be converted into a universal diagnostic error rate.

Detection is not a prognosis

The methods were validated for analytical performance. They did not establish an individual dose, a precise day of prenatal exposure, an exposure route or a causal link to a child’s later clinical outcome.

Different incorporation and deposition patterns can contribute to disagreement. A negative result in one matrix does not mean that every other matrix must be negative, and a more sensitive panel is not automatically a better predictor of harm.

Review the actual report

Interpretation requires the specimen, full analyte names, panel, thresholds and sample preparation. This study supports careful matrix-specific exposure assessment and further outcome research. It does not support diagnosing developmental injury or assigning a precise maternal consumption history from one concentration.

For context, see our discussion of THC concentrations and the separate question of impairment.

Primary research

Triniti L. Jensen and colleagues. Detection of in utero Exposure to Cannabis in Paired Umbilical Cord Tissue and Meconium by Liquid Chromatography-Tandem Mass Spectrometry. Clinical Mass Spectrometry (2019). DOI: 10.1016/j.clinms.2019.01.002.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Oral THC Affected Cognition Without a Parallel Symptom-Scale Increase in a Schizophrenia Study

An oral THC condition worsened selected cognitive outcomes without a significant parallel increase in measured psychotic symptoms several hours later. That combination of findings does not show that THC is harmless in schizophrenia or that all routes have identical effects. Several populations and treatment conditions The double-dummy laboratory study involved…

Spread the love

Read Article: Oral THC Affected Cognition Without a Parallel Symptom-Scale Increase in a Schizophrenia Study

CBD-Associated Liver Enzyme Elevations Occurred Without Reported Liver Symptoms

Healthy adults developed elevated liver enzymes during a four-week CBD trial despite not reporting corresponding liver-related symptoms. The finding shows why the absence of symptoms cannot substitute for the laboratory endpoint being studied. A repeated-dose randomized trial The trial involved 201 healthy participants overall and compared CBD at 5 mg/kg…

Spread the love

Read Article: CBD-Associated Liver Enzyme Elevations Occurred Without Reported Liver Symptoms

CBD–Terpene Sleep Trial: The Average Effect Was Smaller Than the Best-Responder Result

A CBD–terpene trial found a small average change in wearable-estimated sleep stages, while the largest reported improvements occurred in selected responders. Those responder figures should not be presented as the expected benefit for everyone with insomnia. A combined formulation and incomplete datasets The study used 300 mg CBD with eight…

Spread the love

Read Article: CBD–Terpene Sleep Trial: The Average Effect Was Smaller Than the Best-Responder Result

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us